FDA cleared Abivertinib for phase 2 safety and efficacy study in hospitalized patients with moderate to severe COVID-19
On Jul. 20, 2020, Sorrento announced that it had entered into a binding term sheet for an exclusive…
-
-
COVID-19 vaccine AZD1222 showed robust immune responses in all participants in Phase I/II trial
On Jul. 20, 2020, interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed…
-
The Serum Institute of India to apply for local trials of Oxford’s COVID-19 vaccine
On Jul. 20, 2020, the Serum Institute of India (SII) announced that with the trials of the COVID-19…
-
NIH study showed highly reproducible sex differences in aspects of human brain anatomy
On Jul. 20, 2020, a scientific analysis of more than 2,000 brain scans found evidence for highly reproducible…
-
COVID-19 vaccine AZD1222 showed robust immune responses in all participants in Phase I/II trial
On Jul. 20, 2020, AstraZeneca announced that Interim results from the ongoing Phase I/II COV001 trial, led by…
-
Sorrento Announced Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter
On Jul. 20, 2020, Sorrento announced that its partner Mabpharm had received approval of its New Drug Application…
-
Pfizer and BioNTech announced sgreement with the UK for 30 million doses of mRNA-based vaccine candidate against SARS-CoV-2
On Jul. 20, 2020, Pfizer and BioNTech announced an agreement with the United Kingdom to supply 30 million…
-
Oxford Immunotec announced agreement with Stop TB Partnership to access to the T-SPOTTB test for 100+ countries
On Jul. 20, 2020, Oxford Immunotec announced that it had entered into a long-term agreement to supply its…
-
Valneva confirmed participation in UK Government COVID-19 Vaccine Response Program
On Jul. 20, 2020, Valneva confirmed its participation in the UK government COVID-19 vaccine response program. Valneva had…
-
Mateon and Asili Research Alliance entered into partnership for development of Artemisinin against Covid-19
On Jul. 20, 2020, Mateon Therapeutics announced the launch of its global observational study called ARTI-19, for Artemisinin…
-
Innovation Pharma’s Brilacidin inhibited novel Coronavirus by almost 90% at the lowest concentration tested to date in human lung cell line
On Jul. 20, 2020, Innovation Pharma reported receiving new data from ongoing lab testing being conducted at a…
-
OPKO Health’s BioReference Laboratories awarded commercial surge capacity testing for COVID-19 emergency response contract
On Jul. 20, 2020, BioReference Laboratories, an OPKO Health company, announced accepted an Indefinite Delivery Indefinite Quantity contract…
-
Pfizer and BioNTech announced early positive update from German phase 1/2 COVID-19 vaccine study
On Jul. 20, 2020, BioNTech and Pfizer announced initial data from their ongoing German Phase 1/2, open-label, non-randomized,…
-
Thermo Fisher Scientific’s to support development and production of COVID-19 therapeutics and vaccines
On Jul. 20, 2020, Thermo Fisher Scientific expanded global capacity and capabilities across its leading pharma services network…
-
Luminex received FDA Emergency Use Authorization for COVID-19 antibody test
On Jul. 20, 2020, Luminex announced the FDA had issued an Emergency Use Authorization for the company’s xMAPﾮ…
-
HDT BIOﾒs COVID-19 vaccine candidate HDT-301 induced neutralizing antibody responses after single injection
On Jul. 20, 2020, scientists at HDT Bio, PAI Life Sciences, and the University of Washington announced they…
-
HDT Bio partnered with Gennova Biopharmaceuticals to bring COVID-19 vaccine to human trials
On Jul. 19, 2020, HDT Bio announced co-development efforts with Gennova Biopharmaceuticals to start evaluating HDT-301, a COVID-19…
-
FDA authorized Quest Diagnostics COVID-19 diagnostic testing for specimen pooling for emergency use
On Jul. 18, 2020, a Health Trendsﾙ study from researchers at Quest Diagnostics and the University of Pittsburgh…
-
The FDA FDA Issued first Emergency Authorization for sample pooling in diagnostic testing
On Jul. 18, 2020, the FDA reissued an emergency use authorization (EUA) to Quest Diagnostics to authorize its…
-
Novartis launched first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19
On Jul. 16, 2020, Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC;…
-
RedHill Biopharma received approval for phase 2/3 COVID-19 study in Russia
On Jul. 16, 2020, RedHill Biopharma announced approval from the Ministry of Health of the Russian Federation for…
-
Dynavax and Mount Sinai announced collaboration to develop a universal influenza vaccine candidate with CpG 1018 adjuvant
On Jul. 16, 2020, Dynavax Technologies and the Icahn School of Medicine at Mount Sinai announced they had…
-
Heron Therapeutics announced initiation of phase 2 clinical study of CINVANTIﾮ for treatment of COVID-19
On Jul. 16, 2020, Heron Therapeutics announced initiation of the GUARDS-1 Study, a Phase 2 clinical study evaluating…
-
Codex DNA released new synthetic SARS-CoV-2 genome for COVID-19 vaccine and therapeutic research
On Jul. 16, 2020, Codex DNA announced the release of a new synthetic SARS-CoV-2 genome developed to accelerate…
-
Tonix Pharma announced research collaboration to develop precision medicine techniques for COVID-19 vaccines and therapeutics
On Jul. 16, 2020, Tonix Pharmaceuticals announced it had entered into a research collaboration and option agreement with…
-
Atossa Therapeutics contracted for clinical study of AT-301 nasal spray for treating COVID-19
On Jul. 16, 2020, Atossa Therapeutics announced that it has contracted with Avance Clinical to conduct a clinical…
-
Tufts Center for the Study of Drug Development reported faster new drug approval times were more than offset by longer clinical iimes in US
On Jul. 16, 2020, the Tufts Center for the Study of Drug Development reported that although regulatory approval…
-
Atossa Therapeutics announced successful in vitro testing of nasal spray formulation with SARS-CoV-2
On Jul. 15, 2020, Atossa Therapeutics announced successful results from in vitro testing of AT-301, Atossa’s proprietary COVID-19…
-
Cleveland Clinic researchers Identified genetic factors that may Influence COVID-19 susceptibility
On Jul. 15, 2020, A new Cleveland Clinic study identified genetic factors that may influence susceptibility to COVID-19….
-
AXIM Biotechnologies unveiled first-in-class COVID-19 rapid diagnostic test for neutralizing antibodies
On Jul. 15, 2020, AXIM Biotechnologies announced the development of NeuCovixTM, a rapid diagnostic test measuring levels of…
